Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29299640 | 1.00 | HSD17B10 (0.41) | HSD17B10SLC6A9PIK3CDS1PR1SIGMAR1 | |
| SCHEMBL29299636 | 0.95 | SIGMAR1 (0.38) | HSD17B10SLC6A9PIK3CDS1PR1SIGMAR1 | |
| SCHEMBL21764427 | 0.92 | HSD17B10 (0.47) | HSD17B10SLC6A9PIK3CDS1PR1SIGMAR1 | |
| SCHEMBL10284339 | 0.92 | HSD17B10 (0.47) | HSD17B10SLC6A9PIK3CDS1PR1SIGMAR1 | |
| SCHEMBL20202265 | 0.92 | HSD17B10 (0.47) | HSD17B10SLC6A9PIK3CDS1PR1SIGMAR1 | |
| SCHEMBL24220956 | 0.92 | HSD17B10 (0.47) | HSD17B10SLC6A9PIK3CDS1PR1SIGMAR1 | |
| SCHEMBL29299565 | 0.91 | HSD17B10 (0.59) | HSD17B10ALDH1A1 | |
| SCHEMBL18623939 | 0.87 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1SIGMAR1CHRM5 | |
| SCHEMBL21454476 | 0.87 | HSD17B10 (0.42) | HSD17B10SLC6A9S1PR1SIGMAR1CHRM5 | |
| SCHEMBL21764407 | 0.86 | HSD17B10 (0.52) | HSD17B10SLC6A9PIK3CDS1PR1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | PURDUE RESEARCH FOUNDATION | 2024-07-18 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238458-A1 | COMPOUNDS TARGETING FIBROBLAST-ACTIVATION PROTEIN AND METHODS OF USE THEREOF | FAP, FIBP, FGFR1 | HSD17B10 3923/4885SLC6A9 4711/4885PIK3CD 3476/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | HSD17B10 3848/4885SLC6A9 2603/4885PIK3CD 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.